Biotech · Public company · Redwood City, CA, US
Corcept Therapeutics Inc
Ticker CORT · SEC CIK 0001088856
Track this companyFree. Adds Corcept Therapeutics Inc to your Dealase workspace and tells you when its record changes.
Clinical trials258 recruiting or active
Pipeline programs40From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline40
- Nab-paclitaxel 100 mg/m^2Phase 3 · Ovarian NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- Nab-paclitaxel 80 mg/m^2Phase 3 · Ovarian NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- RelacorilantPhase 3 · Cushing SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- RelacorilantPhase 3 · HypercortisolismClinicalTrials.gov · fetched Nov 12, 2026
- Relacorilant 150 mgPhase 3 · Ovarian NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- Bevacizumab 10 mg/kgPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- DazucorilantPhase 2 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Dazucorilant 150 mgPhase 2 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Dazucorilant 300 mgPhase 2 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- EnzalutamidePhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- ExicorilantPhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 2 · AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- MiricorilantPhase 2 · Antipsychotic-induced Weight Gain (AIWG)ClinicalTrials.gov · fetched Nov 12, 2026
- Miricorilant (Cohort A)Phase 2 · Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- Miricorilant (Cohort B)Phase 2 · Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- Nab-paclitaxelPhase 2 · Recurrent Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Nab-paclitaxelPhase 2 · AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Nab-paclitaxel 80 mg/m^2Phase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Nenocorilant 200 mgPhase 2 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Nenocorilant 300 mgPhase 2 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Nenocorilant 400 mgPhase 2 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- RelacorilantPhase 2 · Recurrent Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- RelacorilantPhase 2 · AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Relacorilant 150 mg once daily (QD)Phase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- DazucorilantPhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- DazucorilantPhase 1 · Healthy AdultsClinicalTrials.gov · fetched Nov 12, 2026
- ItraconazolePhase 1 · Healthy AdultsClinicalTrials.gov · fetched Nov 12, 2026
- MiricorilantPhase 1 · Non-alcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- MiricorilantPhase 1 · Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- Miricorilant 10 mgPhase 1 · Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- Miricorilant 100 mgPhase 1 · Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- Miricorilant 150 mgPhase 1 · Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- Miricorilant 50 mgPhase 1 · Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- Miricorilant Treatment APhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Miricorilant Treatment BPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Miricorilant Treatment CPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Miricorilant Treatment DPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Mifepristone 300 MG [Korlym]HypercortisolismClinicalTrials.gov · fetched Nov 12, 2026
- MRI-PDFFNonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol SecretionPHASE1_PHASE2 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07925801 · fetched Nov 12, 2026
- Evaluating the Pharmacokinetics and Safety of MiricorilantPHASE1 · COMPLETED · started Apr 30, 2026ClinicalTrials.gov NCT07553663 · fetched Nov 12, 2026
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaPHASE2 · RECRUITING · started Jan 27, 2026ClinicalTrials.gov NCT07259317 · fetched Nov 12, 2026
- Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesPHASE1_PHASE2 · RECRUITING · started Jan 16, 2026ClinicalTrials.gov NCT07276373 · fetched Nov 12, 2026
- Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult SubjectsPHASE1 · COMPLETED · started Sep 11, 2025ClinicalTrials.gov NCT07240116 · fetched Nov 12, 2026
- Evaluation of Miricorilant on Liver Fat in Patients With MASLDPHASE1 · COMPLETED · started Aug 22, 2025ClinicalTrials.gov NCT06947304 · fetched Nov 12, 2026
- Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersPHASE2 · RECRUITING · started Apr 11, 2025ClinicalTrials.gov NCT06906341 · fetched Nov 12, 2026
- Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)COMPLETED · started Mar 28, 2025ClinicalTrials.gov NCT06829537 · fetched Nov 12, 2026
- Effects of Hepatic Impairment on the Pharmacokinetics of DazucorilantPHASE1 · COMPLETED · started Oct 8, 2024ClinicalTrials.gov NCT06928779 · fetched Nov 12, 2026
- Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult ParticipantsPHASE1 · COMPLETED · started May 31, 2024ClinicalTrials.gov NCT06495944 · fetched Nov 12, 2026
- A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)PHASE2 · COMPLETED · started Oct 25, 2023ClinicalTrials.gov NCT06108219 · fetched Nov 12, 2026
- A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast CancerPHASE2 · RECRUITING · started Oct 18, 2023ClinicalTrials.gov NCT06099769 · fetched Nov 12, 2026
- Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)PHASE4 · COMPLETED · started Mar 31, 2023ClinicalTrials.gov NCT05772169 · fetched Nov 12, 2026
- Dazucorilant in Patients With Amyotrophic Lateral SclerosisPHASE2 · ACTIVE_NOT_RECRUITING · started Nov 15, 2022ClinicalTrials.gov NCT05407324 · fetched Nov 12, 2026
- Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 29, 2022ClinicalTrials.gov NCT05257408 · fetched Nov 12, 2026
- A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)COMPLETED · started Mar 4, 2022ClinicalTrials.gov NCT05320146 · fetched Nov 12, 2026
- Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of MiricorilantPHASE1 · COMPLETED · started Mar 3, 2022ClinicalTrials.gov NCT05553470 · fetched Nov 12, 2026
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)PHASE1 · COMPLETED · started Nov 23, 2021ClinicalTrials.gov NCT05117489 · fetched Nov 12, 2026
- A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasPHASE3 · COMPLETED · started Jul 27, 2020ClinicalTrials.gov NCT04308590 · fetched Nov 12, 2026
- A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic MedicationsPHASE2 · COMPLETED · started Dec 4, 2019ClinicalTrials.gov NCT03818256 · fetched Nov 12, 2026
- Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerPHASE2 · COMPLETED · started Apr 5, 2019ClinicalTrials.gov NCT03776812 · fetched Nov 12, 2026
- A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromePHASE3 · COMPLETED · started Nov 15, 2018ClinicalTrials.gov NCT03697109 · fetched Nov 12, 2026
- Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate CancerPHASE1 · COMPLETED · started Oct 23, 2018ClinicalTrials.gov NCT03674814 · fetched Nov 12, 2026
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromePHASE2 · ACTIVE_NOT_RECRUITING · started May 7, 2018ClinicalTrials.gov NCT03604198 · fetched Nov 12, 2026
- Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerPHASE1_PHASE2 · TERMINATED · started Feb 20, 2018ClinicalTrials.gov NCT03437941 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 23, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jul 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 28, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 25, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 24, 2026 · fetched Nov 12, 2026